A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
ConditionMultifocal Motor Neuropathy
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorDianthus Therapeutics
About this trial
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of Claseprubart (DNTH103) in participants with multifocal motor neuropathy (MMN).
Eligibility criteria
Qualifiers
Must have given written informed consent before any study-related activities are carried out
Adult males and females, 18 to 75 years of age (inclusive).
Weight range between 40 to 120 kilograms (kg).
Confirmed diagnosis of definite or probable MMN.
Disqualifiers
History or presence of significant medical/surgical condition including any acute illness or major surgery considered to be clinically significant or that could impact efficacy assessments.
Any coexisting conditions which may interfere with outcome assessments (eg, severe diabetic neuropathy).
Concurrent or previous use of rituximab, cyclophosphamide, mycophenolate mofetil, azathioprine, or cyclosporine. If a participant has previously used these medications, the last dose must be at least 6 months prior to randomization.
Currently or previously on complement inhibitors including in a clinical trial setting.
Trial design
Treatments tested in this trial
- Claseprubart
- Placebo
Treatment groups
36 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov